Skip Navigation



Schizophrenia Bulletin Advance Access published online on April 4, 2007
Schizophrenia Bulletin, doi:10.1093/schbul/sbm027
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
33/3/633    most recent
sbm027v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Carpenter, W. T.
Right arrow Articles by Thaker, G. K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Carpenter, W. T.
Right arrow Articles by Thaker, G. K.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2007. Published by Oxford University Press on behalf of the Maryland Psychiatric Research Center. All rights reserved. For permissions, please email: journals.permissions@oxfordjournals.org.

Editorial: Evidence-Based Therapeutics—Introducing the Cochrane Corner

William T. Carpenter and Gunvant K. Thaker
The first 10% of the full text of this article appears below.

Therapeutic advances in schizophrenia are challenging, and novel drug development strategies that target diverse mechanisms are wanting. The drug discovery process has diverged little from the initial strategy of targeting D2 dopamine receptors following the discovery of the antipsychotic effect of chlorpromazine. The superior efficacy of clozapine in treatment-resistant patients was touted as a big advance in schizophrenia therapeutics promising superior effectiveness of the second-generation drugs in treating psychosis as well as other symptom domains and cognition impairments of schizophrenia. As suggested by the commercial success of these drugs, clinicians and consumers enthusiastically bought . . . [Full Text of this Article]

1 To whom correspondence should be addressed; e-mail: wcarpent@mprc.umaryland.edu


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Psychiatr. Serv.Home page
R. A. Rosenheck, D. L. Leslie, and J. A. Doshi
Second-Generation Antipsychotics: Cost-Effectiveness, Policy Options, and Political Decision Making
Psychiatr Serv, May 1, 2008; 59(5): 515 - 520.
[Abstract] [Full Text] [PDF]

Home page
 Schizophr BullHome page
C. E. Adams, E. S. F. Coutinho, J. Davis, L. Duggan, S. Leucht, C. Li, and P. Tharyan
Cochrane Schizophrenia Group
Schizophr Bull, March 1, 2008; 34(2): 259 - 265.
[Full Text] [PDF]